Novel B-Cell targeting therapy with subcutaneous of atumumab in AQP4-IgG-seronegative Neuromyelitis Optica Spectrum Disorders: efficacy and personalized dosing - PubMed
8 hours ago
- #ofatumumab
- #neuromyelitis optica
- #B-cell therapy
- Two AQP4-IgG-seronegative NMOSD patients (13-year-old male, 31-year-old female) with severe disability showed significant clinical improvement after personalized subcutaneous ofatumumab therapy.
- Patients achieved rapid and sustained B-cell depletion (CD19+% 0.00-0.11%), no relapses, and EDSS scores decreased by ≥3 points over 18-20 months, with lesion reduction on MRI.
- Dosing interval was successfully extended to every two months after 12 months of monthly therapy, maintaining efficacy and safety with no serious adverse events.
- Subcutaneous ofatumumab demonstrated efficacy and safety as a long-term treatment for AQP4-IgG-seronegative NMOSD, supporting its use as a promising therapeutic option.